Posters

Jun 2022

ASCO – Oral Presentation

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

Jun 2022

ASCO

TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

May 2022

ESMO Breast

Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) to placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast carcinoma.

Mar 2022

ELCC

Results from a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients

Nov 2021

SITC

Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

Publications

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.

Brignone, C., M. Gutierrez, F. Mefti, E. Brain, R. Jarcau, F. Cvitkovic, N. Bousetta, J. Medioni, J. Gligorov, C. Grygar, M. Marcu, and F. Triebel. 2010. J Transl Med 8:71.

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma.

Brignone, C., B. Escudier, C. Grygar, M. Marcu, and F. Triebel. 2009. Clinical Cancer Research 15:6225.

A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells.

Brignone, C., C. Grygar, M. Marcu, K. Schakel, and F. Triebel. 2007. J Immunol 179:4202.

A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.

Triebel, F., K. Hacene, and M. F. Pichon. 2006. Cancer Lett 235:147.

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.

Triebel, F. 2003. Trends Immunol 24:619.